Bufotenin
| 5-HO-DMT | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 204.27 g/mol [1] |
| Melting point | 146.5 °C [1] |
| Predicted LogP | 1.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H16N2O |
| IUPAC name | 3-[2-(dimethylamino)ethyl]-1H-indol-5-ol |
| SMILES | CN(C)CCC1=CNC2=C1C=C(C=C2)O |
| InChI | InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3 |
| InChIKey | VTTONGPRPXSUTJ-UHFFFAOYSA-N |
| CAS number | 487-93-4 |
| UNII | 0A31347TZK |
| PubChem CID | 10257 |
| Pharmacokinetics[] | |
|---|---|
| Onset | Oral administration: 20 min, Intranasal administration: 5–15 min, Sublingual administration: 5–15 min, Rectal administration: ~15 min, Inhalational administration: ≤1–2 min, Intravenous injection: <1 min |
| Duration of action | Oral administration: ~2 hours, Intranasal administration: 30–90 min, Sublingual administration: 30–90 min, Rectal administration: ~1 hour, Inhalational administration: 60–90 min, Intravenous injection: ~5–120 min |
| Metabolism | Deamination via monoamine oxidase A and conjugation (glucuronidation, sulfation) |
| Routes of administration | Oral, intranasal/insufflation, inhalation, sublingual, rectal, intravenous |
Bufotenin (also known as N,N-Dimethylserotonin, Mappine, N,N-Dimethyl-5-hydroxytryptamine, Mappin, Dimethylserotonin, Cohoba, 5-Hydroxy-N,N-dimethyltryptamine, Dm5-ht, 3-(2-Dimethylaminoethyl)-5-indolol or N,N-Dimethyl-5-HT) is a psychedelic substance of the tryptamine class.
Chemistry
Stereochemistry []
Bufotenin is achiral.
Druglikeness
Lipinski's rule of five
Bufotenin matches Lipinski's rule of five.Reagents
There are currently 3 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | green > brown | |
| Ehrlich | green / blue | |
| Hofmann | green |
Pharmacology
MeSH Classification
Experience reports
Legal status []
- Australia: Bufotenin is a Schedule 9.
- Canada: Bufotenin is Unscheduled.
- Germany: Bufotenin is a Neuer psychoaktiver Stoff under the "Neue-psychoaktive-Stoffe-Gesetz (NpSG)".
- United Kingdom: Bufotenin is a Class A under the "Misuse of Drugs Act 1971".
- United States: Bufotenin is a Schedule I under the "Controlled Substances Act".
- Other: Bufotenin is a Illegal in Sweden.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 10257, Bufotenin. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/10257
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Bufotenin. UNII: 0A31347TZK. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/0A31347TZK
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 15:01:36 |
| drugspro | ok | 2026-11-20 15:01:32 |
| erowid | ok | 2026-11-20 15:01:34 |
| gsrs | ok | 2026-11-20 15:01:32 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0041842) | 2026-11-20 15:01:32 |
| kegg | missing (no KEGG DRUG entry) | 2026-11-20 15:01:36 |
| pubchem | ok | 2026-11-20 15:01:32 |
| missing (no r/tripreports posts mention it) | 2026-11-20 15:01:32 | |
| sider | missing (not in SIDER) | 2026-11-20 15:01:32 |
| structure | ok | 2026-11-20 15:01:32 |
| wikipedia | ok | 2026-11-20 15:01:32 |